[Type 1 and type 2 interferon inductor (cycloferon) in therapy of children with pyelonephritis associated with herpes viruses].
The clinical and laboratory efficacy of the treatment of children with pyelonephritis with addition of cycloferon, an inductor of early interferon of types 1 and 2, to the main therapy was studied. The mechanism of the cycloferon action was described. The clinical and laboratory remission within a year was observed in 64.3% of the patients treated with addition of cycloferon vs. 47.1% of the patients under the main therapy without the cycloferon addition. The number of the relapses lowered to 7.1% vs. 20.6% of the episodes in the control group. The minimal risk of the disease exacerbation (0.37) in the patients treated with cycloferon and the relative risk of the unfavourable outcomes among the patients under the therapy with addition of cycloferon (0.5967< or =1) were determined.
Orekhova
S B
SB
Botvin'ev
O K
OK
Romantsov
M G
MG
D000166:Acridines / Q000008:administration & dosage* / Q000009:adverse effects; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006564:Herpesviridae; D006566:Herpesviridae Infections / Q000150:complications / Q000628:therapy* / Q000821:virology; D006801:Humans; D007369:Interferon Inducers / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011704:Pyelonephritis / Q000209:etiology / Q000628:therapy* / Q000821:virology; D012307:Risk Factors
D000166:Acridines; D007369:Interferon Inducers; C026430:10-carboxymethyl-9-acridanone